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AbstrACt
Objective Because most children with asthma now 
use inhaled corticosteroids (ICS), the added benefit 
of immunotherapy in asthmatic children needs to 
be examined. We re-assessed the effectiveness of 
subcutaneous (SCIT) and sublingual immunotherapy 
(SLIT) in childhood asthma treatment focusing on 
studies with patient-relevant outcome measures and 
children using ICS.
Methods We used the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
approach to systematically search and appraise the 
evidence using predefined critical patient-relevant 
outcomes (asthma symptoms, asthma control and 
exacerbations). We searched to retrieve systematic 
reviews and randomised controlled trials on 
immunotherapy for asthma in children (1960–2017). We 
assessed the quality of the body of evidence with GRADE 
criteria.
results The quality of the evidence for SCIT was very 
low due to a large risk of bias and indirectness (dated 
studies in children not using ICS). No effect of SCIT 
was found for asthma symptoms; no studies reported 
on asthma control. For asthma exacerbations, studies 
favoured SCIT. We have little confidence in this effect 
estimate, due to the very low quality of evidence. For 
SLIT, quality of the evidence was very low due to a large 
risk of bias, indirectness and imprecision. The outcome 
‘asthma symptoms’ could not be calculated due to lack 
of standardisation and large clinical heterogeneity. Other 
predefined outcomes were not reported.
Conclusion The beneficial effects of immunotherapy in 
childhood asthma found in earlier reviews are no longer 
considered applicable, because of indirectness (studies 
performed in children not being treated according to 
current asthma guidelines with ICS). There was absence 
of evidence to properly determine the effectiveness or 
lack thereof of immunotherapy in asthma treatment in 
children with ICS.
IntrOduCtIOn 
Asthma affects 10%–15% of school-aged chil-
dren. For children with persistent asthma, all 
international guidelines recommend daily 
controller treatment with inhaled corticoste-
roids (ICS), and reliever medication (short-
acting β-2-agonists) as needed.1 2 Although 
many children achieve complete asthma 
control using this effective and safe treat-
ment,1 some need additional treatment to 
obtain disease control.3 4 Identification and 
treatment of comorbidities in children with 
problematic severe asthma is part of the step-
wise approach to improve asthma control in 
these children.5 6 
strengths and limitations of this study
 ► This study is the first review evaluating 
immunotherapy in asthmatic children using 
the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach, 
focusing more on clinically relevant than on 
statistically significant differences in patient-
relevant outcomes.
 ► By using GRADE, we identified indirectness in 
previous systematic reviews in this field, which 
highlights a lack of applicable evidence.
 ► A strength of the study is the use of predefined 
clinically relevant patient outcomes, rather than 
statistically significant differences.
 ► A general limitation of a systematic review is the 
use of aggregated data, that, in theory might mask 
potential specific results.
 ► This study has focused on critically appraising 
earlier evidence for nowadays practice, rather than 
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The most common of these comorbidities in chil-
dren with asthma is allergic rhinitis,5 symptoms of which 
occur in 60%–80% of asthmatic children.7 8 Allergic 
rhinitis shares a common pathophysiological pathway 
with asthma, which has been described as the united 
airway concept.9 Allergic rhinitis is associated with worse 
asthma control in children, and accumulating evidence 
suggests that treatment of allergic rhinitis with intranasal 
steroids improves rhinitis and asthma symptoms in these 
patients.7 10 11
When symptoms of allergic rhinitis cannot be suffi-
ciently controlled with nasal corticosteroids and oral 
antihistamines,9 12 immunotherapy can be considered as 
additional treatment.13 Subcutaneous immunotherapy 
(SCIT) requires repeated injections with an allergen 
extract and is available for allergens such as grass and tree 
pollen and house dust mite. After disappointing results 
of low-dose preparations in drops, effective high-dose 
sublingual immunotherapy (SLIT) has now become avail-
able with grass pollen allergen extract in a daily sublin-
gual tablet.14 15 A Cochrane systematic review (SR), first 
published in 2000, and last updated in 2010, reported 
beneficial effects of immunotherapy in children with 
asthma.16 Multiple studies in this latter review, however, 
were performed before or in the 1980s, when most chil-
dren with asthma were not using ICS.
As part of the update of the Dutch paediatric guideline 
on childhood asthma, we evaluated the literature on the 
added value of SCIT and SLIT in childhood asthma.17 Our 
structured clinical question was to assess whether immu-
notherapy (subcutaneous or sublingual), as an add-on to 
usual care with daily ICS, improves asthma outcomes in 
children (6–12 years) and adolescents (>12 years) with 
persistent asthma and sensitisation to relevant aeroaller-
gens (grass or tree pollen, house dust mite or combina-
tions), with or without symptoms of allergic rhinitis.
MethOds
We used GRADE approach (Grading of Recommen-
dations Assessment, Development and Evaluation) to 
appraise and summarise the body of evidence. GRADE 
is an internationally approved standard for managing 
complex evidence reviews.18 In contrast to former grading 
systems, GRADE focuses on the quality of the total body 
of evidence, instead of judging single studies. Another 
important characteristic of GRADE is that predefined 
outcomes with thresholds for clinical relevance are 
being used.19 In earlier grading systems, the evidence 
was summarised using outcomes reported in studies, not 
necessarily being outcomes a guideline development 
group would be interested in.20 GRADE avoids the use of 
surrogate or intermediate outcomes, and uses outcomes 
and differences that are more clinically relevant to 
patients instead. Starting from a SR, for each outcome the 
quality of evidence can be downgraded or upgraded, for 
instance based on risk of bias, inconsistency, indirectness, 
possible publication bias and dose–response relation.
The guideline development group included an epide-
miologist, paediatric respiratory physicians, paediatri-
cians, an allergist, an ear-nose-throat specialist, a family 
physician, a lung function technician, a youth public 
healthcare physician and patient representatives. The 
guideline development group predefined clinically rele-
vant outcomes and divided these into critical (contrib-
uting to the overall quality of evidence), important 
(also relevant to the content of the guideline) and not 
important outcomes. For each outcome, a minimal clin-
ically important difference was defined a priori. The 
outcomes taken into account in our literature review are 
summarised in table 1, with corresponding minimal clini-
cally important differences.21–24
We applied a sensitive search strategy to retrieve all avail-
able evidence addressing the clinical question, focusing 
on SRs about asthma and immunotherapy in children. 
Literature searches were performed in March 2012 for 
the guideline (from 1960 onwards), and updated in April 
2015 for the purpose of this review. A second update, 
including an expansion of the searching scope, was 
performed in June 2017 (see online supplementary table 
E1). In the original search, we searched in the Cochrane 
Database of Systematic Reviews, the Database of Abstracts 
of Reviews of Effectiveness and the Cochrane Central 
Trial Register. In the 2017 update, we also searched for 
SRs in the Medline and Embase databases (again from 
1960 onwards). Two reviewers (EJG and MKT) inde-
pendently screened the abstracts using predefined 
inclusion criteria: methodology (SRs), patients (chil-
dren with allergic asthma) and SCIT and/or SLIT as 
Table 1 Patient-relevant outcomes and clinical relevance
Outcome Importance Minimal clinically important difference
Asthma symptoms Critical ACT: 3, c-ACT: (2–)3*
(Severe) exacerbations Critical NNT, n=10
Asthma control Critical ACT: 3, c-ACT: (2–)3*
(Disease-specific) quality of life Important PAQLQ: 0.5 (scale 0–7)*
Change in FEV1 Important >5% predicted
*Or comparable differences on other valid scales representing this outcome.
ACT, asthma control test; c-ACT, child asthma control test; FEV1, forced expiratory volume in 1 s; NNT, number needed to treat (to prevent 








pen: first published as 10.1136/bmjopen-2017-016326 on 28 December 2017. Downloaded from 
 3van de Griendt E-J, et al. BMJ Open 2017;7:e016326. doi:10.1136/bmjopen-2017-016326
Open Access
an intervention. Animal studies, conference abstracts 
and studies published in languages other than English, 
Dutch and German were excluded. Differences between 
reviewers were resolved by consensus. Selected abstracts 
were critically appraised with respect to study population, 
intervention and methodological aspects (eg, systematic 
search and selection, inclusion of randomised controlled 
trials (RCTs)), which led to a further selection. An expert 
in the field (HdG) judged the selection for completeness.
All included studies were summarised in evidence 
tables by two reviewers (EJG and MKT). SRs were criti-
cally appraised using the AMSTAR checklist (A Measure-
ment Tool to Assess Systematic Reviews).25 AMSTAR 
scores range from 0 to 11, a higher score indicating better 
quality (less bias). The Jadad scale was used to assess the 
methodological quality of each included RCT.26 This 
score ranges from 0 to 5, a higher score denoting a better 
quality. All eligible studies together defined the body of 
evidence, of which the quality was determined (per rele-
vant outcome and overall quality) and GRADE profiles 
were created. Results from SRs and RCTs were pooled, 
if possible, in meta-analyses using RevMan V.5. We calcu-
lated standardised mean differences for continuous 
outcomes, because of the usage of different symptom 
scales in the underlying studies. We calculated risk ratios 
for dichotomous outcomes, to compare the probability 
of these outcomes between the intervention and control 
groups. In the meta-analyses we used random effects 
models, because of the possibility of generalisation of the 
outcomes for different allergens, and tested the differ-
ence between intervention and control with the inverse 
variance method, since this method is typically used in 
meta-analyses to combine the results of independent 
studies. We reported 95% CIs (predefined significance 
level: 0.05). Conclusions were drawn, based on quality 
and content, per outcome and discussed in the expert 
group until consensus was reached.
Patient involvement
The guideline development group included patient 
representatives who helped defining our clinical ques-
tion, approved outcome measures and assessed its clin-
ical relevancy. The burden of interventions and patient 
considerations were assessed as part of GRADE evalua-
tion. Patients were not directly involved in this SR since 
we reviewed published literature.
results
literature search and selection
Screening of titles and abstracts yielded 83 eligible 
studies, 10 of which fulfilled the inclusion criteria.16 27–35 
After examining these 10 papers in full, five more studies 
were excluded (figure 1).
Experts in the guideline working group confirmed that 
no relevant publications were missed. The updated search 
(April 2015) revealed 43 additional studies, of which 2 
fulfilled the inclusion criteria.36 37 Full text examination 
resulted in exclusion of these two studies. The extended 
and updated search in June 2017 resulted in 177 hits, 
of which 6 were selected to full paper study.38–43 These 
studies were SRs in the field of SCIT and/or SLIT in chil-
dren with asthma. Most of the included RCTs in these 
reviews had already been included in the 2015 search. We 
only added RCTs of those reviews to our meta-analyses 




We retrieved one Cochrane SR on the effectiveness of 
SCIT in patients with asthma, including 90 RCTs with 
a total of 3792 patients.16 This was a high-quality review 
(AMSTAR score 10/11). Fourteen of the included RCTs 
were performed in children exclusively; another 24 
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included children and adults. In a few studies the age 
inclusion criteria were not clear. The characteristics of 
these review are summarised in an evidence table (see 
online supplementary table E2).16 29 32 Only nine RCTs 
included in these reviews reported on our predefined 
outcomes in children.45–53 In these nine studies different 
allergens or combinations were studied (house dust mite 
(3), dog dander (1), grass pollen (1), mould (1), grass 
pollen/house dust mite (1) and tailored combinations 
(2)). Two RCTs published after the 2010 Cochrane review 
were retrieved.34 35 In the first, the clinical efficacy of 
house dust mite-specific SCIT in 20 asthmatic children 
was compared with no intervention in 20 others; patients 
were followed up for 6 months.34 In the other, the effects 
of allergen-specific SCIT on corticosteroid dose in asth-
matic children were evaluated.35 Details of all included 
RCTs are summarised in the evidence table (see online 
supplementary table E3).34 35 45–53
Quality of the evidence
Little information was given about the included studies 
in the Cochrane review; for example, follow-up was not 
stated. There were also other concerns about the quality 
of the literature, for example, not all studies were double 
blind and placebo controlled, and randomisation proce-
dures were poor. Therefore we re-analysed the indi-
vidual paediatric studies in the Cochrane review, plus the 
added studies.34 35 Jadad scores of the single studies are 
presented in table 2.
The quality of the body of evidence for all critical and 
important outcomes was very low (table 3), mainly due 
to large risk of bias and indirectness. The large risk of 
bias was caused by a lack of allocation concealment, lack 
of information on follow-up and loss to follow-up. The 
reason for downgrading for indirectness was the publi-
cation year of the underlying studies; populations and 




Four small studies carried out in children only reported 
this outcome in the Cochrane review.16 We extracted 
these results from the Cochrane review and updated these 
with the results from Tsai et al.34 Results are presented in 
figure 2.
The meta-analysis showed no significant effect of SCIT 
on asthma symptoms.
Asthma exacerbations
Five studies (published 1961–1984) in the Cochrane 
review, carried out in children only, reported this 
outcome.16 No relevant studies of sufficient quality were 
published afterwards. Our meta-analysis included 253 
patients on immunotherapy and 153 on placebo. The 
pooled risk ratio was 0.47 (95%CI 0.31 to 0.72), favouring 
immunotherapy (see figure 3). The absolute risk reduc-
tion was 35%, giving a number needed to treat of 3.
No studies reported results on the critical outcome 
asthma control.
Important outcomes
No studies reported results on quality of life or lung func-
tion (forced expiratory volume in 1 s (FEV1)).
results of slIt
Description of studies and quality of the evidence
We retrieved two SRs on SLIT in patients with asthma.29 32 
The updated search in 2017 resulted in the addition of 
one RCT.44 The characteristics of the SRs are summarised 
in evidence table (see online supplementary table E2). 
The quality of the reviews was moderate; both had 
an AMSTAR score of 7/11. Weaknesses included the 
absence of an ‘a priori design’, exclusion of grey litera-
ture, not assessing the likelihood of publication bias and 
not mentioning conflicts of interest in one review,29 and 
the absence of an a priori design, no information about 
excluded studies, too firm conclusions compared with 
the weak evidence and not assessing the likelihood of 
publication bias in the other.32 One review included both 
children and adults, and patients with asthma and/or 
rhinitis.29 Because of the quality concerns of both existing 
SRs, we set out to perform a meta-analysis of the original 
studies that fulfilled our selection criteria. Jadad scores of 
selected studies, as well as an overview of the outcomes of 
those studies, are presented in table 4.24 29 32 44 54–67 Study 
characteristics are summarised in the evidence table (see 
online supplementary table E4).44 54 55 57 58 60 63–65 We rated 
the quality of evidence to be very low, due to a large risk 
of bias, imprecision and indirect evidence.
Critical outcomes
Asthma symptoms
Eight of the included studies reported on asthma symp-
toms. Different symptom scores were used, none of them 
Table 2 Jadad scores of RCTs on SCIT
Randomisation* Blinding† Withdrawals‡ Total
Adkinson et al45 1 1 1 3
Altintas et al46 1 1 1 3
Dreborg et al47 1 – – 1
Hill et al48 1 – – 1
Johnstone et al49 2 1 – 3
Johnstone et al50 2 1 1 4
Price et al51 1 1 – 3
Tsai et al34 1 – 1 2
Valovirta et al52 1 – 1 2
Warner et al53 1 1 1 3
Zielen et al35 1 1 1 3
*1 point if randomisation is mentioned; 1 additional point if the method of 
randomisation is appropriate; −1 point if the method of randomisation is 
inappropriate.
†1 point if blinding is mentioned; 1 additional point if the method of blinding 
is appropriate; −1 point if the method of blinding is inappropriate.
‡1 point if the number and the reasons for withdrawal in each group are 
stated.
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standardised or validated. Clinical differences in asthma 
scores were not defined and most studies reported 
improvement in the treatment group as well in the 
control group. We were not able to compile a meta-anal-
ysis of the results of the individual studies, because of the 
use of various symptom scales in the included studies. 
Since studies did not report results in a clearly compa-
rable way, reporting the results of the individual studies 
was considered unreliable.
Other critical outcomes
No studies reported results on the critical outcomes exac-
erbations and asthma control.
Important outcomes
Quality of life
Pham-Thi et al published results on quality of life using 
Childhood Asthma Questionnaires.44 The authors 
reported a difference in severity between SLIT and 
placebo in the younger population (age 6–11 years), but 
not in older children (age 12–16 years). It is not stated 
whether this difference is clinically relevant.
Lung function
Four studies reported results on lung function (FEV1). 
One of the studies reported no numeric data on lung 
function.64 One study reported no variance (SD), and 
no comparison of the baseline data.63 The two remaining 
studies reported on FEV1 percentage predicted,
58 and 
reported no significant differences between treatment 
groups, neither at baseline nor at follow-up.
dIsCussIOn
summary of main results
Our GRADE SR showed no evidence of a significant differ-
ence in asthma symptoms between SCIT and placebo in 
children with allergic asthma, but some evidence for a 
significant and clinically relevant reduction in asthma 
exacerbations was found in SCIT-treated children. We 
have little confidence in the effect estimate, however, 
due to a large risk of bias and indirectness. Thus, the true 
effect of SCIT on exacerbations and asthma symptoms in 
the target population of interest is likely to be substan-
tially different from the estimate of effect. There was 
absence of evidence on the effects of SCIT on lung func-
tion, asthma control and quality of life in children with 
allergic asthma. There was no evidence for a beneficial 
effect of SLIT in reducing asthma symptoms and exacer-
bations, quality of life and lung function in children with 
allergic asthma. Our review does not address the efficacy 
of immunotherapy in children regarding complaints of 
allergic rhinitis and/or conjunctivitis, without having 
asthma.
Quality of the evidence/GrAde methodology
The overall quality of the evidence about the effective-
ness of SCIT and SLIT was very low. This implicates that 
our confidence in the effect estimates is very limited. The 
true effect of SCIT and SLIT on patient-relevant asthma 
outcomes in children with asthma may be substantially 
different from our estimates of the effect. We cannot 
conclude that the possible desirable effects of SCIT and 
Figure 2 Meta-analysis of SCIT versus placebo, outcome asthma symptoms. IV, inverse variance; Random, random effect 
model; SCIT, subcutaneous immunotherapy; Std, standardised.
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SLIT outweigh the undesirable effects (eg, influence on 
quality of life, adverse events or increased resource expen-
diture), nor can we reject that hypothesis. Our concerns 
about the quality of evidence are based on (very) serious 
risk of bias and indirectness in the underlying primary 
studies. First, the quality of many studies had to be down-
graded because of risk of bias due to lack of allocation 
concealment, lack of information on follow-up and loss to 
follow-up. Second, included studies were heterogeneous 
in the patients included and allergen extracts used, with 
different dosing regimens and duration being studied, 
targeting different inhaled allergens. We have concerns 
about the potential different responses and the general-
isability of the evidence. Thirdly, and most importantly, 
for SCIT, the quality of the body of evidence was down-
graded because of indirectness, since patients in the orig-
inal studies long ago are likely to differ considerably from 
patients nowadays.
Fourth, different studies used variable definitions 
of asthma exacerbations. We had to use ‘worsening of 
asthma’, which may not represent real-life patient-rele-
vant exacerbations. This may decrease the applicability 
of the evidence. In addition, there were no studies using 
the predefined important outcomes quality of life and 
asthma control.
Finally, and most importantly, we have concerns on 
comparability of patients. Several included studies dated 
from the 1980s or earlier, when allergic rhinitis treat-
ment with selective antihistamines and nasal corticoste-
roids was not available. Against the background of the 
united airway concept, the comorbidity allergic rhinitis 
in patients in these studies cannot be compared with 
patients in clinical practice today.9 Similarly, widespread 
use of ICS was not introduced in childhood asthma treat-
ment until the 1990s.68 Most studies on SCIT in chil-
dren with asthma were published decades ago, during 
the pre-ICS era. Although SCIT appeared to be effec-
tive in some of the included studies,49 50 we cannot draw 
conclusions from these findings, because the patients in 
the described studies represent an incomparable group 
when compared with the child with asthma in contem-
porary clinical practice. Specifically, it is unclear whether 
the beneficial effects found in the SR of earlier studies 
are applicable to children with asthma treated according 
to contemporary guidelines with daily ICS controller 
therapy.16
In our opinion and that of others, GRADE approach 
is superior to former methods of SRs, because it focuses 
on predefined patient-relevant outcomes, predefined 
minimally clinical important differences and because it 
judges the complete body of evidence. One RCT among 
paediatricians studied the influence of different guide-
line grading systems on clinician’s decisions.69 GRADE 
showed the largest change in direction on the clinical 
decision. However, the added value of GRADE on guide-
line implementation or patient care has not been formally 
evaluated, GRADE approach is still rather complex for 
non-methodologists.
To formulate recommendations for clinical practice, 
not only the body of evidence concerning effectiveness of 
an intervention is important. Recommendations should 
balance the benefits and harms of the intervention of 
interest, and take patient preferences and resource use 
into account. Since (after critical evaluation) no bene-
fits of SCIT and SLIT for children with asthma were 
determined, we consider it unlikely that the benefits will 
exceed the harms. Patient preferences were included in 
the formulation of our guideline recommendations.
Agreements and disagreements with other studies or reviews
Using GRADE and re-analysing data from children with 
allergic asthma only, we came to different conclusions 
on the effectiveness of SCIT and SLIT in children with 
asthma than the authors of the original SRs. We believe 
this highlights the importance of using GRADE meth-
odology to systematically review evidence for patient-rel-
evant outcomes, not focusing on levels of evidence, but 
on underlying study validity, precision, directness and 
applicability in current clinical practice. The 2009 posi-
tion paper on SLIT describes history, use and applica-
bility of this treatment for allergic rhinitis.70 It positions 
SLIT in children as a safe and useful therapy above and 
after more regular treatment for allergic rhinitis. Poten-
tial positive treatment outcome for allergic asthma is 
however mainly based on literature in adults. We show 
the lack of evidence and lack of applicability of treatment 
of immunotherapy for asthma in children. Since we have 
worries on the applicability of evidence in adults on chil-
dren (who are still developing their immune system), we 
think further studies that compare immunotherapy for 
the contemporary treatment of asthma in children are 
urgently needed to fill in this gap.
Recently, a Cochrane SR on SLIT for asthma found a 
similar lack of data for important outcomes (eg, exacer-
bations, symptom scores and quality of life) as we did.71 
Contrary to our study, the authors did no separate anal-
ysis for adults and children, and patients with asthma were 
not separately analysed from patients without asthma.
COnClusIOns
Focusing on predefined patient-relevant outcomes, and 
critically appraising the body of evidence using original 
studies and GRADE methodology, our SR on the effects 
of immunotherapy in children with asthma came to 
different conclusions than previous SRs. We believe that 
this underscores the importance of using GRADE meth-
odology in systematically reviewing evidence.
We found absence of valid applicable evidence on 
improvement of clinically relevant asthma outcomes in 
children with allergic asthma using SCIT or SLIT. This 
absence of evidence is due to serious risk of bias, large 
clinical heterogeneity between studies and most impor-
tantly due to lack of applicability because studies were 
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Since the effect of immunotherapy added to contem-
porary asthma treatment with daily controller therapy is 
not clear, the drawbacks of immunotherapy should be 
considered carefully. SCIT is a complex and intensive 
form of treatment, associated with a (very) long duration 
of treatment, and considerable burden to the patient 
with (monthly) injections under adequate medical super-
vision due to potential (however rare) dangerous side 
effects, and may have relatively high costs and resource 
use. In SLIT the risk of serious side effects is consider-
ably smaller, but the other drawbacks of immunotherapy 
apply equally to this treatment. In our opinion therefore, 
when balancing the absence of evidence on a clear bene-
ficial effect of SCIT or SLIT on clinically relevant patient 
outcomes in children with asthma with the considerable 
burden and costs of SCIT and SLIT, we do not recom-
mend this treatment to children with asthma until further 
high-quality evidence from well-designed RCTs in chil-
dren comparing SCIT or SLIT to contemporary asthma 
treatment becomes available.
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